A bill would slow the revolving door between pharma and federal agencies

Should there be a doorstop in the revolving door between drug makers and regulatory agencies?

Several U.S. senators believe so, and on Thursday they introduced legislation  that would take two steps to slow the pace at which individuals move between the pharmaceutical industry and both the Food and Drug Administration and the Drug Enforcement Administration.

To wit, the bill would increase the prohibition on former senior regulators lobbying the federal government from one to two years, and expand the definition of “lobbying contact” to include any lobbying activities and strategy.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus in-depth analysis, newsletters, premium events, and networking platform access.

Already have an account? Log in

Already have an account? Log in

Individual plans

Group plans

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe

Log In